Welcome to our dedicated page for LakeShore Co SEC filings (Ticker: LSBWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LSBWF SEC filings page on Stock Titan is intended to provide access to regulatory disclosures associated with LakeShore Biopharma Co., Ltd and its related securities. Although specific filings are not listed in the provided data, the company has stated that it remains a reporting company with the U.S. Securities and Exchange Commission, even after its transition from The Nasdaq Capital Market to the OTC Pink Open Market.
LakeShore Biopharma’s disclosed regulatory actions include its announcement that Nasdaq issued a delisting determination based on non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and ineligibility for a further compliance period under Listing Rule 5810(c)(3)(A)(iv). Following this determination, the company reported that trading of its ordinary shares and warrants on Nasdaq was suspended and that the securities began trading on the OTC Pink Open Market under LSBCF and LSBWF.
In addition, LakeShore Biopharma has announced that it will furnish a current report on Form 6‑K to the SEC regarding its Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. The company has also stated that it will prepare and mail a proxy statement to shareholders and file a Schedule 13E‑3 transaction statement with the SEC in connection with the going‑private merger. These documents are expected to describe the terms of the merger, the treatment of ordinary shares, and the role of rollover shareholders.
On Stock Titan, SEC filings for LSBWF and related LakeShore Biopharma securities can be paired with AI-powered summaries that explain the structure and implications of documents such as Forms 6‑K, proxy statements, and Schedule 13E‑3. This helps readers understand how listing changes, merger agreements, and other regulatory events affect the company’s capital structure and the status of its OTC‑traded warrants and shares.
LakeShore Biopharma’s major shareholders have amended their go‑private deal, sharply cutting the proposed cash payout to public investors. The Amended Merger Agreement reduces the per share merger consideration from US$0.90 to US$0.066, implying about US$1.3 million to buy out outstanding ordinary shares not held by rollover shareholders. The lead reporting person, Huaqin Xue, is deemed to beneficially own 21,021,332 ordinary shares, or 51.0% of the company based on 41,212,693 shares outstanding as of June 30, 2025. Several funds, including Oceanpine, Adjuvant, MSA Growth, Superstring and Epiphron, report smaller holdings below 2% each. Termination fees are also reduced to US$50,000 for the company and US$100,000 for the parent. If the merger closes, LakeShore Biopharma’s ordinary shares would be deregistered and cease trading on the OTC Pink Open Market.
LakeShore Biopharma’s major shareholders have amended their go‑private deal, sharply cutting the proposed cash payout to public investors. The Amended Merger Agreement reduces the per share merger consideration from US$0.90 to US$0.066, implying about US$1.3 million to buy out outstanding ordinary shares not held by rollover shareholders. The lead reporting person, Huaqin Xue, is deemed to beneficially own 21,021,332 ordinary shares, or 51.0% of the company based on 41,212,693 shares outstanding as of June 30, 2025. Several funds, including Oceanpine, Adjuvant, MSA Growth, Superstring and Epiphron, report smaller holdings below 2% each. Termination fees are also reduced to US$50,000 for the company and US$100,000 for the parent. If the merger closes, LakeShore Biopharma’s ordinary shares would be deregistered and cease trading on the OTC Pink Open Market.
LakeShore Biopharma entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going‑private transaction implying an equity value of approximately US$2.7 million. Each ordinary share will be cancelled for US$0.066 in cash, other than excluded and dissenting shares.
The new per‑share cash price, described as amended merger consideration, is reduced from US$0.90 to US$0.066 but represents premiums of about 46.7% to the March 24, 2026 closing price and 23.3% to the 10‑day volume‑weighted average price. Termination fees are cut to US$50,000 for the company and US$100,000 for the parent, and the termination date is extended to nine months from the amendment date.
The board, acting on the unanimous recommendation of a three‑member independent Special Committee, approved the amended deal and recommends shareholder approval. Rollover shareholders holding about 53.35% of voting rights agreed to support the merger. Closing is currently expected in the third quarter of 2026, after customary conditions and a shareholder vote. If completed, LakeShore Biopharma will become privately held and its shares will cease trading on the OTC Pink Open Market.
LakeShore Biopharma entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. for a going‑private transaction implying an equity value of approximately US$2.7 million. Each ordinary share will be cancelled for US$0.066 in cash, other than excluded and dissenting shares.
The new per‑share cash price, described as amended merger consideration, is reduced from US$0.90 to US$0.066 but represents premiums of about 46.7% to the March 24, 2026 closing price and 23.3% to the 10‑day volume‑weighted average price. Termination fees are cut to US$50,000 for the company and US$100,000 for the parent, and the termination date is extended to nine months from the amendment date.
The board, acting on the unanimous recommendation of a three‑member independent Special Committee, approved the amended deal and recommends shareholder approval. Rollover shareholders holding about 53.35% of voting rights agreed to support the merger. Closing is currently expected in the third quarter of 2026, after customary conditions and a shareholder vote. If completed, LakeShore Biopharma will become privately held and its shares will cease trading on the OTC Pink Open Market.
LakeShore Biopharma Co., Ltd. director and President/CBO Shao Hui David filed an initial ownership report showing holdings of Ordinary Shares. He directly owns 133,360 Ordinary Shares and is also deemed to beneficially own 180,278 Ordinary Shares held indirectly through Mountainview Investment Holdings LLC, which he wholly controls as a director.
LakeShore Biopharma Co., Ltd. director and President/CBO Shao Hui David filed an initial ownership report showing holdings of Ordinary Shares. He directly owns 133,360 Ordinary Shares and is also deemed to beneficially own 180,278 Ordinary Shares held indirectly through Mountainview Investment Holdings LLC, which he wholly controls as a director.
LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.
LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director Xue Linnan has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes their status as a director and formally begins periodic ownership reporting, but does not itself reflect any buy or sell transaction.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma reported that its board’s special committee has received a revised, preliminary and non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares they do not already own for US$0.06 per share in cash.
The bidders referenced arbitral awards totaling approximately RMB576.5 million against certain PRC subsidiaries, which they believe constitute a “Company Material Adverse Effect” under the existing November 2025 merger agreement and give them the right not to close on current terms. The special committee will evaluate the lower-priced offer, and the company stresses there is no assurance any definitive offer, agreement, or transaction will ultimately be completed.